Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
NCT07428746 on ClinicalTrials.gov · last registry update 2026-08-03
A small phase 3 — 20 participants, against a typical 424. Due to report November 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Change in handgrip strength. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Emory University
- Sponsor type
- Other
- Enrollment
- 20
- Started
- 2026-05-07
- Primary completion
- 2028-11 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in handgrip strength
Conditions studied
Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.